search
Back to results

Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer

Primary Purpose

Gastric Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Robotic distal gastrectomy with D2 nodal dissection
Laparoscopic distal gastrectomy with D2 nodal dissection
Sponsored by
Southwest Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer focused on measuring laparoscopy-assisted gastrectomy, robot-assisted gastrectomy, advanced gastric cancer, D2 Lymphadenectomy

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Pathologically proven gastric adenocarcinoma.
  2. Tumor located in the lower third of the stomach, and is possible to be curatively resected by subtotal gastrectomy.
  3. Preoperative stage of cT2-4aN0-3M0 according to American Joint Committee on Cancer/Union for International Cancer Control 8th edition
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. American Society of Anesthesiology (ASA) score of class I to III
  6. Patients who freely give informed consent to participate in the clinical study

Exclusion Criteria:

  1. Previous upper abdominal surgery (except laparoscopic cholecystectomy)
  2. Previous gastric resection (gastrectomy, endoscopic mucosal resection, or endoscopic submucosal dissection)
  3. Gastric cancer-related complications (complete obstruction or perforation)
  4. Enlarged or bulky regional lymph node diameter larger than 3 cm based on preoperative imaging
  5. Previous neoadjuvant chemotherapy or radiotherapy for gastric cancer
  6. Patients diagnosed with other malignancy within 5 years
  7. Severe mental disorder
  8. Unstable angina or myocardial infarction within the past 6 months
  9. Cerebrovascular accident within the past 6 months
  10. Severe respiratory disease (FEV1< 50%)
  11. Continuous systemic steroid therapy within 1 month before the study
  12. Pregnant or breast-feeding women

Sites / Locations

  • Chinese PLA general hospital
  • Peking University Cancer Hospital
  • Department of General Surgery and Center of Microinvasive Gastrointestinal Surgery, Southwest Hospital
  • Fujian Medical University Union Hospital
  • Lanzhou PLA General Hospital
  • Sun Yat-sen University Cancer Center
  • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  • The Second Xiangya Hospital of Central South University
  • Nanjing General Hospital
  • The First Affiliated Hospital of Nanchang University
  • Jilin Cancer Hospital
  • The Affiliated Hospital of Qingdao University
  • Xijing Hospital of Digestive Dieases
  • West China Hospital, Sichuan University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Robotic gastrectomy

Laparoscopic gastrectomy

Arm Description

Robotic distal gastrectomy with D2 nodal dissection

Laparoscopic distal gastrectomy with D2 nodal dissection

Outcomes

Primary Outcome Measures

3-year relapse-free survival
Relapse-free survival is defined as days from surgery to recurrence or death from any cause, and it is censored at the latest day when the patient is alive without any evidence of recurrence.

Secondary Outcome Measures

Morbidity
Early postoperative morbidity confined to events that occur within 30 days after surgery. The complications that occur after postoperative day 30 belong to late postoperative morbidity
Mortality
Postoperative mortality is defined to death that occurs within 30 days.
3-year overall survival
Overall survival is defined as days from surgery to death from any cause, and it is censored at the last day when the patient was alive.
3-year recurrence pattern
Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.
Postoperative recovery course
Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay are used to assess the postoperative recovery course.
Inflammatory response
The daily highest body temperature before discharge and the values of white blood cell count (10^9/L), hemoglobin (g/L), C-reactive protein (mg/L) and prealbumin (mg/L) from peripheral blood before operation and on postoperative day 1, 3, 5, 7 are recorded.
Immune response
The values of relevant immune cytokines from peripheral blood before operation and on postoperative day 1, 3, 5, 7 are recorded.

Full Information

First Posted
August 23, 2017
Last Updated
September 5, 2017
Sponsor
Southwest Hospital, China
Collaborators
Chinese PLA General Hospital, West China Hospital, Xijing Hospital of Digestive Diseases, Nanjing PLA General Hospital, Peking University Cancer Hospital & Institute, Qingdao University, Fujian Medical University Union Hospital, Central South University, The First Affiliated Hospital of Nanchang University, Sun Yat-sen University, Wuhan Union Hospital, China, Jilin Provincial Tumor Hospital, Lanzhou General Hospital of PLA
search

1. Study Identification

Unique Protocol Identification Number
NCT03273920
Brief Title
Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
Official Title
Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer: a Multicenter Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 25, 2017 (Anticipated)
Primary Completion Date
September 25, 2019 (Anticipated)
Study Completion Date
September 25, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Southwest Hospital, China
Collaborators
Chinese PLA General Hospital, West China Hospital, Xijing Hospital of Digestive Diseases, Nanjing PLA General Hospital, Peking University Cancer Hospital & Institute, Qingdao University, Fujian Medical University Union Hospital, Central South University, The First Affiliated Hospital of Nanchang University, Sun Yat-sen University, Wuhan Union Hospital, China, Jilin Provincial Tumor Hospital, Lanzhou General Hospital of PLA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is an investigator-initiated, randomized, controlled, parallel group, and non-inferiority trial comparing robot-assisted gastrectomy with D2 nodal dissection for locally advanced gastric cancer patients with laparoscopic procedure.
Detailed Description
Since the first case of laparoscopy-assisted distal gastrectomy was reported in 1994, the number of patients undergoing the laparoscopic procedure has gradually increased. The latest Japanese gastric cancer treatment guideline recommends laparoscopic gastrectomy (LG) as an optional treatment for cStage I gastric cancer (GC). Based on the experience of early GC, most experienced surgeons have applied the laparoscopic procedure in patients with locally advanced gastric cancer (AGC). According to the results of large-scaled retrospective studies and ongoing randomized controlled trials (RCTs), LG treating AGC can gain better short-term outcomes and comparable long-term oncologic results. To minimize the limitations of laparoscopic surgery, robot systems have been introduced to treat GC providing technical advantages. Though the feasibility and safety of robotic gastrectomy (RG) have been well accepted, the benefits of RG remain controversial. A recent meta-analysis including eleven studies of 3503 patients demonstrated that RG indicated potentially favorable outcomes in terms of blood loss compared with LG. Furthermore, it has been confirmed that robotic system could provide an advantage over LG in the dissection of the N2 area lymph nodes, especially around the splenic artery area. Our previous study demonstrated that the RG had less intraoperative blood loss and more lymph nodes dissection compared with the laparoscopic procedure. However, the only prospective study reported that RG is not superior to LG in terms of perioperative surgical outcomes. Nevertheless, the following subgroup analysis found that patients with GC undergoing D2 lymph node dissection can benefit from less blood loss when a robotic surgery system is used. Take together, RG with D2 nodal dissection may be superior laparoscopic surgery in terms of blood loss and retrieved lymph nodes. However, lack of high-level evidence-based medical researches, we can't drew a conclusion that patients with AGC may benefit from RG with D2 nodal dissection. With regard to a new surgical approach, oncologic safety has attracted more attention. Although some retrospective studies have demonstrated that RG with lymphadenectomy for GC had non-inferior oncologic outcome relative to LG, there is no prospective RCT to evaluate the long-term outcomes of RG. Therefore, the Chinese Robotic Gastrointestinal Surgery Study (CRASS) Group launched a multicenter prospective RCT to verify the short-term and long-term outcomes of RG in AGC. The primary objective of this study is to assess whether robot-assisted distal gastrectomy is comparable to laparoscopic approach in terms of long-term oncologic outcomes without compromising relapse-free survival. The secondary research objectives are to compare robotic and laparoscopic approach in terms of morbidity, mortality, quality of life, cost-effectiveness, and overall survival.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
laparoscopy-assisted gastrectomy, robot-assisted gastrectomy, advanced gastric cancer, D2 Lymphadenectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Robotic gastrectomy
Arm Type
Experimental
Arm Description
Robotic distal gastrectomy with D2 nodal dissection
Arm Title
Laparoscopic gastrectomy
Arm Type
Active Comparator
Arm Description
Laparoscopic distal gastrectomy with D2 nodal dissection
Intervention Type
Procedure
Intervention Name(s)
Robotic distal gastrectomy with D2 nodal dissection
Intervention Description
After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic distal gastrectomy with D2 nodal dissection
Intervention Description
After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
Primary Outcome Measure Information:
Title
3-year relapse-free survival
Description
Relapse-free survival is defined as days from surgery to recurrence or death from any cause, and it is censored at the latest day when the patient is alive without any evidence of recurrence.
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Morbidity
Description
Early postoperative morbidity confined to events that occur within 30 days after surgery. The complications that occur after postoperative day 30 belong to late postoperative morbidity
Time Frame
30 days
Title
Mortality
Description
Postoperative mortality is defined to death that occurs within 30 days.
Time Frame
30 days
Title
3-year overall survival
Description
Overall survival is defined as days from surgery to death from any cause, and it is censored at the last day when the patient was alive.
Time Frame
3 years
Title
3-year recurrence pattern
Description
Recurrence patterns are classified into five categories at the time of first diagnosis: locoregional, hematogenous, peritoneal, distant lymph node, and mixed type.
Time Frame
3 years
Title
Postoperative recovery course
Description
Time to first ambulation, flatus, liquid diet, soft diet, and duration of hospital stay are used to assess the postoperative recovery course.
Time Frame
15 days
Title
Inflammatory response
Description
The daily highest body temperature before discharge and the values of white blood cell count (10^9/L), hemoglobin (g/L), C-reactive protein (mg/L) and prealbumin (mg/L) from peripheral blood before operation and on postoperative day 1, 3, 5, 7 are recorded.
Time Frame
7 days
Title
Immune response
Description
The values of relevant immune cytokines from peripheral blood before operation and on postoperative day 1, 3, 5, 7 are recorded.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathologically proven gastric adenocarcinoma. Tumor located in the lower third of the stomach, and is possible to be curatively resected by subtotal gastrectomy. Preoperative stage of cT2-4aN0-3M0 according to American Joint Committee on Cancer/Union for International Cancer Control 8th edition Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 American Society of Anesthesiology (ASA) score of class I to III Patients who freely give informed consent to participate in the clinical study Exclusion Criteria: Previous upper abdominal surgery (except laparoscopic cholecystectomy) Previous gastric resection (gastrectomy, endoscopic mucosal resection, or endoscopic submucosal dissection) Gastric cancer-related complications (complete obstruction or perforation) Enlarged or bulky regional lymph node diameter larger than 3 cm based on preoperative imaging Previous neoadjuvant chemotherapy or radiotherapy for gastric cancer Patients diagnosed with other malignancy within 5 years Severe mental disorder Unstable angina or myocardial infarction within the past 6 months Cerebrovascular accident within the past 6 months Severe respiratory disease (FEV1< 50%) Continuous systemic steroid therapy within 1 month before the study Pregnant or breast-feeding women
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peiwu Yu, M.D.
Phone
+86023-68754161
Email
yupeiwu01@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peiwu Yu, M.D.
Organizational Affiliation
Southwest Hospital, China
Official's Role
Study Chair
Facility Information:
Facility Name
Chinese PLA general hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100853
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lin Chen, M.D.
Facility Name
Peking University Cancer Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiangqian Su, M.D.
Facility Name
Department of General Surgery and Center of Microinvasive Gastrointestinal Surgery, Southwest Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400038
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu Pei Wu, M.D.
Phone
008602368754146
Email
yupeiwu01@sina.com
First Name & Middle Initial & Last Name & Degree
Shi Yan, M.D.
Phone
008602368765267
Email
shiyandoctor@sina.com
First Name & Middle Initial & Last Name & Degree
Pei Wu Yu, M.D.
First Name & Middle Initial & Last Name & Degree
Yan Shi, M.D.
Facility Name
Fujian Medical University Union Hospital
City
Fuzhou
State/Province
Fujian
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Changmin Huang, M.D.
Facility Name
Lanzhou PLA General Hospital
City
Lanzhou
State/Province
Gansu
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongbin Liu, M.D.
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhiwei Zhou, M.D.
Facility Name
Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kaixiong Tao, M.D.
Facility Name
The Second Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongliang Yao, M.D.
Facility Name
Nanjing General Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhiwei Jiang, M.D.
Facility Name
The First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Taiyuan Li, M.D.
Facility Name
Jilin Cancer Hospital
City
Changchun
State/Province
Jilin
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Longwei Cheng, M.D.
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yanbing Zhou, M.D.
Facility Name
Xijing Hospital of Digestive Dieases
City
Xi'an
State/Province
Shanxi
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jipeng Li, M.D.
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jiankun Hu, M.D.

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
8180768
Citation
Kitano S, Iso Y, Moriyama M, Sugimachi K. Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994 Apr;4(2):146-8. Erratum In: Surg Laparosc Endosc. 2013 Oct;23(5):480.
Results Reference
background
PubMed Identifier
21512884
Citation
Zhao Y, Yu P, Hao Y, Qian F, Tang B, Shi Y, Luo H, Zhang Y. Comparison of outcomes for laparoscopically assisted and open radical distal gastrectomy with lymphadenectomy for advanced gastric cancer. Surg Endosc. 2011 Sep;25(9):2960-6. doi: 10.1007/s00464-011-1652-y. Epub 2011 Apr 22.
Results Reference
background
PubMed Identifier
24651893
Citation
Hu Y, Ying M, Huang C, Wei H, Jiang Z, Peng X, Hu J, Du X, Wang B, Lin F, Xu J, Dong G, Mou T, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Oncologic outcomes of laparoscopy-assisted gastrectomy for advanced gastric cancer: a large-scale multicenter retrospective cohort study from China. Surg Endosc. 2014 Jul;28(7):2048-56. doi: 10.1007/s00464-014-3426-9. Epub 2014 Mar 21.
Results Reference
background
PubMed Identifier
26903580
Citation
Hu Y, Huang C, Sun Y, Su X, Cao H, Hu J, Xue Y, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Chen P, Liu H, Zheng C, Liu F, Yu J, Li Z, Zhao G, Chen X, Wang K, Li P, Xing J, Li G. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol. 2016 Apr 20;34(12):1350-7. doi: 10.1200/JCO.2015.63.7215. Epub 2016 Feb 22.
Results Reference
background
PubMed Identifier
26170158
Citation
Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, Yoshida K, Takagane A, Kojima K, Sakuramoto S, Shiraishi N, Kitano S. A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901). World J Surg. 2015 Nov;39(11):2734-41. doi: 10.1007/s00268-015-3160-z.
Results Reference
background
PubMed Identifier
11984681
Citation
Hashizume M, Shimada M, Tomikawa M, Ikeda Y, Takahashi I, Abe R, Koga F, Gotoh N, Konishi K, Maehara S, Sugimachi K. Early experiences of endoscopic procedures in general surgery assisted by a computer-enhanced surgical system. Surg Endosc. 2002 Aug;16(8):1187-91. doi: 10.1007/s004640080154. Epub 2002 May 3.
Results Reference
background
PubMed Identifier
24385251
Citation
Junfeng Z, Yan S, Bo T, Yingxue H, Dongzhu Z, Yongliang Z, Feng Q, Peiwu Y. Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: comparison of surgical performance and short-term outcomes. Surg Endosc. 2014 Jun;28(6):1779-87. doi: 10.1007/s00464-013-3385-6. Epub 2014 Jan 3.
Results Reference
background
PubMed Identifier
27129542
Citation
Nakauchi M, Suda K, Susumu S, Kadoya S, Inaba K, Ishida Y, Uyama I. Comparison of the long-term outcomes of robotic radical gastrectomy for gastric cancer and conventional laparoscopic approach: a single institutional retrospective cohort study. Surg Endosc. 2016 Dec;30(12):5444-5452. doi: 10.1007/s00464-016-4904-z. Epub 2016 Apr 29.
Results Reference
background
PubMed Identifier
28639136
Citation
Obama K, Kim YM, Kang DR, Son T, Kim HI, Noh SH, Hyung WJ. Long-term oncologic outcomes of robotic gastrectomy for gastric cancer compared with laparoscopic gastrectomy. Gastric Cancer. 2018 Mar;21(2):285-295. doi: 10.1007/s10120-017-0740-7. Epub 2017 Jun 21.
Results Reference
background
PubMed Identifier
28582378
Citation
Duan BS, Zhao J, Xie LF, Wang Y. Robotic Verse Laparoscopic Gastrectomy for Gastric Cancer: A Pooled Analysis of 11 Individual Studies. Surg Laparosc Endosc Percutan Tech. 2017 Jun;27(3):147-153. doi: 10.1097/SLE.0000000000000410.
Results Reference
background
PubMed Identifier
26020107
Citation
Kim HI, Han SU, Yang HK, Kim YW, Lee HJ, Ryu KW, Park JM, An JY, Kim MC, Park S, Song KY, Oh SJ, Kong SH, Suh BJ, Yang DH, Ha TK, Kim YN, Hyung WJ. Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg. 2016 Jan;263(1):103-9. doi: 10.1097/SLA.0000000000001249.
Results Reference
background
PubMed Identifier
27514719
Citation
Park JM, Kim HI, Han SU, Yang HK, Kim YW, Lee HJ, An JY, Kim MC, Park S, Song KY, Oh SJ, Kong SH, Suh BJ, Yang DH, Ha TK, Hyung WJ, Ryu KW. Who may benefit from robotic gastrectomy?: A subgroup analysis of multicenter prospective comparative study data on robotic versus laparoscopic gastrectomy. Eur J Surg Oncol. 2016 Dec;42(12):1944-1949. doi: 10.1016/j.ejso.2016.07.012. Epub 2016 Jul 29.
Results Reference
background

Learn more about this trial

Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer

We'll reach out to this number within 24 hrs